How Data-Driven Process Development Is Transforming Phosphoramidite Manufacturing

As oligonucleotide therapeutics continue to expand across areas such as rare diseases, oncology, and infectious diseases, manufacturers face increasing pressure to produce high-quality phosphoramidites with greater consistency, scalability, and cost efficiency. A data-driven process development strategy is helping address these challenges by applying Design of Experiments (DoE) methodologies to better understand the factors that influence product quality, impurity formation, and manufacturing performance.

Using DMT-d(T) phosphoramidite as a practical example, optimized process conditions achieved product purities above 98% while maintaining strong yields and reducing reliance on extensive chromatographic purification. The result is a more efficient manufacturing process that lowers complexity, supports scale-up, and improves commercial viability. Beyond a single product, the same development framework can be applied across a broad range of phosphoramidites, including custom nucleotide building blocks that enable differentiated oligonucleotide platforms.

For drug developers, robust process understanding can accelerate development timelines, reduce risk, strengthen supply chains, and support the advancement of next-generation DNA- and RNA-based therapeutics.